Allied Market Research published a report, titled, ‘mRNAVaccines and RNAi Therapeutics Market by Disease Type (Hereditary transthyretin-mediated amyloidosis genetic, Acute hepatic porphyria, Primary hyperoxaluria type 1, Atherosclerotic cardiovascular disease), by Route of administration (IV infusion, Subcutaneous), by End user (Research Institutes, Hospitals and clinics): Global Opportunity Analysis and Industry Forecast, 2022-2031.’ According to the report, the global mRNA vaccines and RNAi therapeutics industry generated $707.97 million in 2021, and is anticipated to generate $12.31 billion by 2031, witnessing a CAGR of 31.3% from 2022 to 2031.
Download Report (245 Pages PDF with Insights, Charts, Tables, Figures): https://www.alliedmarketresearch.com/request-sample/17623
Leading Market Players: –
- Alnylam Pharmaceuticals
- BioNTech AG
- Curevac AG
- Etherna Immunotherapies
- Ethris GMBH
- IN-CELL-ART
- Moderna Therapeutics
- Sangamo Therapeutics, Inc.
- Sanofi AG
- SCM Life Sciences (Argos Therapeutics, Inc.
- Sarepta Therapeutics
- Arcturus Therapeutics
- Ionis Pharmaceuticals, Inc
- Nutcracker
- Tiba Biotech
mRNA Vaccines and RNAi Therapeutics Market Report Highlights
Disease Type
- Hereditary transthyretin-mediated amyloidosis genetic
- Acute hepatic porphyria
- Primary hyperoxaluria type 1
- Atherosclerotic cardiovascular disease
Route of administration
- IV infusion
- Subcutaneous
End user
- Research Institutes
- Hospitals and clinics
Specific Requirement on COVID-19? Ask to Our Industry Expert: https://www.alliedmarketresearch.com/request-for-customization/17623?reqfor=covid